J&J Claims Guidant For $23.9 Bil., Forms CV Device Group Under Valeriani
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's willingness to pay $24 bil. (6.5-times revenue) for Guidant validates the long-standing claim of ICD manufacturers that the cardiac rhythm management market is largely underserved
You may also be interested in...
J&J/Guidant To Divest Peripheral Devices To Meet EC Competition Rules
Johnson & Johnson has agreed to divest Guidant's European peripheral stent business as a condition of the European Commission's approval of the planned acquisition
J&J/Guidant To Divest Peripheral Devices To Meet EC Competition Rules
Johnson & Johnson has agreed to divest Guidant's European peripheral stent business as a condition of the European Commission's approval of the planned acquisition
J&J May Seek Better Deal For Guidant After ICD Recalls Lower Stock Price
Johnson & Johnson will likely ask Guidant to lower its acquisition price by roughly $2 bil. after recent ICD recalls pushed Guidant's stock price down approximately 10%